

IN THE CLAIMS:

42. (NEW) A pharmaceutical compound comprising an amino acid motif of the formula
 $Y_1-X_1-X_2-Y_2-Y_3-Y_4-X_3-X_4-X_5-Y_5-X_6-X_7-X_8-X_9-X_{10}-Y_6$

where

Y_1 is Asn or Gln;

Y_2 is a negatively charged amino acid selected from the group consisting of Glu and Asp;

Y_3 is Ile, Leu, Val or Met;

Y_4 is a negatively charged amino acid selected from the group consisting of Glu and Asp;

Y_5 is aromatic amino acid selected from the group consisting of Trp, Phe, Tyr and His;

Y_6 is aromatic amino acid selected from the group consisting of Tyr Trp, Phe and His; and,

$X_1, X_2, X_3, X_4, X_5, X_6, X_7, X_8, X_9$, and X_{10} are, independently, any amino acid;

said compound capable of specific binding with high affinity VEGF receptor.

43. (NEW) The compound according to Claim 1, wherein said compound comprises an amino acid sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, and SEQ. ID. NO.:7.

44. (NEW) A pharmaceutical composition comprising the compound of claim 42 and a biological agent.

45. (NEW) A pharmaceutical composition comprising the compound of claim 42 and a carrier.

46. (NEW) The pharmaceutical compound of claim 42, wherein the compound further comprises a biological agent conjugated thereto.

47. (NEW) The pharmaceutical compound of claim 42, wherein the compound further comprises a modified biological agent conjugated thereto.

48. (NEW) The pharmaceutical compound of claim 42, wherein a therapeutic agent is conjugated thereto.

49. (NEW) A method of treating a disease associated with angiogenesis in a patient in need of such therapy comprising administering to said patient an effective amount of said pharmaceutical compound of claim 42 and a pharmaceutically acceptable carrier.

50. (NEW) An isolated nucleic acid encoding a polypeptide comprising an amino acid motif of the formula: $Y_1-X_1-X_2-Y_2$, $Y_3-Y_4-X_3-X_4-X_5-Y_5-X_6-X_7-X_8-X_9-X_{10}-Y_6$ or an analog of said peptide wherein

Y_1 is Asn or Gln;

Y_2 is Glu or Asp;

Y_3 is Ile, Leu, Val or Met;

Y₄ is Glu or Asp;

Y₅ is aromatic amino acid comprising of Trp, Phe, Tyr or His

Y₆ is aromatic amino acid comprising of Tyr Trp, Phe or His; and,

X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, and X₁₀ are, independently, any amino acid.

51. (NEW) The isolated nucleic acid of claim 50 encoding a polypeptide having an amino acid sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, and SEQ. ID. NO.:7.

52. (NEW) An expression vector comprising the nucleic acid sequence of claim 51.

53. (NEW) A host cell transfected with the expression vector of claim 52.

54. (NEW) A composition comprising a nucleic acid molecule and carrier, wherein the nucleic acid molecule encodes a polypeptide comprising an amino acid motif of the formula:

Y₁-X₁-X₂-Y₂-Y₃-Y₄-X₃-X₄-X₅-Y₅-X₆-X₇-X₈-X₉-X₁₀-Y₆

Y₁ is Asn or Gln;

Y₂ is a negatively charged amino acid selected from the group consisting of Glu and Asp;

Y₃ is Ile, Leu, Val or Met;

Y₄ is a negatively charged amino acid selected from the group consisting of Glu and Asp;

Y₅ is aromatic amino acid selected from the group consisting of Trp, Phe, Tyr and His;

Y₆ is aromatic amino acid selected from the group consisting of Tyr Trp, Phe and His; and,

X₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈, X₉, and X₁₀ are, independently, any amino acid.

55. (NEW) The composition of claim 55 wherein said nucleic acid molecule encodes a polypeptide having an amino acid sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, and SEQ. ID. NO.:7.